Inferra AI / Company / JNJ / Slides
Johnson & Johnson — Q3 2026 Earnings Presentation
Johnson & Johnson (JNJ) · 0 slides · Filed Oct 20, 2026
Every slide of this earnings presentation, with the text as published. Open the original deck ↗ · All JNJ deck slides
Slide 1 — 1
1
Slide 2 — 3rd Quarter 2026
3rd Quarter 2026 Earnings Call October 13, 2026
Slide 3 — Cautionary note on Forward-looking statements
Cautionary note on Forward-looking statements This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The viewer is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, investor.jnj.com, or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Cautionary note on Non-GAAP financial measures This presentation refers to certain non-GAAP financial measures. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the Company’s website. 3
Slide 4 — Strategic partnerships, collaborations
Oncology IMBRUVICA developed in collaboration and co-marketed in the U.S. with Pharmacyclics, LLC, an AbbVie company; ZYTIGA licensed from BTG International Ltd.; VELCADE developed in collaboration with Millennium: The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO licensed from Genmab A/S; BALVERSA licensed and discovered in collaboration with Astex Pharmaceuticals, Inc.; ERLEADA licensed from Regents of California and Memorial Sloan Kettering; CARVYKTI licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited; AKEEGA licensed from TESARO, Inc., an oncology-focused business within GSK, and from BTG International Ltd.; RYBREVANT developed under license with Genmab A/S; LAZCLUZE licensed from Yuhan Corporation; DuoBody platform licensed from Genmab A/S relates to several bispecific antibody programs; OMT animal platform licensed from OMT Inc. relates to several antibody programs; ENHANZE platform licensed from Halozyme Therapeutics, Inc.; bleximenib R&D co-funding agreement with Blackstone Life Sciences Immunology REMICADE marketing partner with Mitsubishi Tanabe Pharma Corporation; TREMFYA discovered using MorphoSys AG antibody technology; ICOTYDE was discovered through a collaboration with Protagonist Therapeutics – Janssen retains exclusive rights to develop and commercialize for a broad range of indications; JNJ-4804 R&D co-funding agreement with Royalty Pharma plc Neuroscience INVEGA SUSTENNA/ XEPLION/ INVEGA TRINZA/ TREVICTA/ INVEGA HAFYERA/ BYANNLI are subject to a technology license agreement from Alkermes Pharma Ireland Limited, and RISPERDAL CONSTA developed in collaboration with Alkermes, Inc. Other PREZCOBIX / REZOLSTA fixed-dose combination, SYMTUZA and ODEFSEY developed in collaboration with Gilead Sciences, Inc., and JULUCA and CABENUVA developed in collaboration with ViiV Healthcare UK., INVOKANA/ INVOKAMET/ VOKANAMET/ INVOKAMET XR fixed-dose combination licensed from Mitsubishi Tanabe Pharma Corporation; XARELTO co-developed with Bayer HealthCare AG; PROCRIT/ EPREX licensed from Amgen Inc.; UPTRAVI license and supply agreement with Nippon Shinyaku (co-promotion in Japan), and OPSUMIT co-promotion agreement with Nippon Shinyaku in Japan Strategic partnerships, collaborations & licensing arrangements During the course of this presentation, we will discuss a number of products and compounds developed in collaboration with strategic partners or licensed from other companies. The following is an acknowledgement of those relationships: 4
Slide 5 — Agenda
CEO Remarks Sales performance and earnings review Capital allocation and guidance update Q&A Agenda 5 John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Ryan Koors Vice President, Investor Relations Tom Cavanaugh Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, MedTech 1 2 3 4
Slide 6 — Joaquin Duato
Joaquin Duato Chairman and Chief Executive Officer
Slide 7 — 6.0%
Q3 Earnings Summary 6.0% operational sales growth 1,2 Six key businesses driving growth 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes an approximate (420) basis point headwind from STELARA Cardiovascular Oncology Immunology Neuroscience Vision Surgery 7
Slide 8 — 29 Platforms / Products > 1 Billion in Annual Sales
29 Platforms / Products > 1 Billion in Annual Sales Innovative Medicine (16) MedTech (13) Electrophysiology Contact Lenses Surgical Vision Biosurgery Trauma Shockwave Abiomed Knees Hips Spine Energy Endocutters Wound Closure 8
Slide 9 — Innovative Medicine: 7.9% operational sales growth
Innovative Medicine: 7.9% operational sales growth 1,2 Oncology Neuroscience Immunology 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Includes an approximate (690) basis point headwind from STELARA 9
Slide 10 — MedTech: 2.5% operational sales growth
MedTech: 2.5% operational sales growth 1 Cardiovascular Surgery Vision VARIPULSE Platform Dual Energy THERMOCOOL SMARTTOUCH SF Catheter Shockwave Intravascular Lithotripsy System OMNYPULSE Catheter Impella® Heart Pump Technology OTTAVA Robotic Surgical System ETHICON 4000 Surgical Stapler with 3D Stapling Technology ACUVUE® OASYS 1-Day Family TECNIS Odyssey TECNIS PureSee 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Includes existing products and planned future launches SURGIFLO Hemostatic Matrix Kit STRATAFIX Knotless Tissue Control Devices 10
Slide 11 — OTTAVA
OTTAVA U.S. FDA market authorization opens a new category in surgical robotics De Novo authorization spans 10 general surgery procedures, including: • Gastric bypass • Gastric sleeve Occupies 30–50% less space than boom- and cart-mounted systems Connects to the Polyphonic open digital ecosystem for data-driven insights First commercial customer signed Inguinal hernia trial in progress The world’s first table-integrated soft tissue robotic system — four arms built into a standard surgical table Surgery OTTAVATM Robotic Surgical System • Cholecystectomy • Hiatal hernia repair 11
Slide 12 — MedTech: 2.5% operational sales growth
MedTech: 2.5% operational sales growth 1 Cardiovascular Surgery Vision VARIPULSE Platform Dual Energy THERMOCOOL SMARTTOUCH SF Catheter Shockwave Intravascular Lithotripsy System OMNYPULSE Catheter Impella® Heart Pump Technology OTTAVA Robotic Surgical System ETHICON 4000 Surgical Stapler with 3D Stapling Technology ACUVUE® OASYS 1-Day Family TECNIS Odyssey TECNIS PureSee 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Includes existing products and planned future launches SURGIFLO Hemostatic Matrix Kit STRATAFIX Knotless Tissue Control Devices 12
Slide 13 — Johnson & Johnson is built
Johnson & Johnson is built for durable growth 13
Slide 14 — Ryan Koors
Ryan Koors Vice President, Investor Relations
Slide 15 — 3rd Quarter 2026 sales
Regional sales results Q3 2026 Q3 2025 % Change Reported Operational1 U.S. $15.0 $13.7 9.1% 9.1% Europe 5.4 5.4 (0.6) 1.0 Western Hemisphere (ex U.S.) 1.4 1.2 12.5 8.0 Asia-Pacific, Africa 3.7 3.6 1.0 1.0 International 10.4 10.3 1.5 1.8 Worldwide (WW) $25.4 $24.0 5.9% 6.0% Dollars in billions 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 3rd Quarter 2026 sales 15
Slide 16 — 3rd Quarter 2026 financial highlights
$25.4 $24.0 $6.34 $6.8 (7.5)%; (6.8)%1 $2.594 $2.80 Dollars in billions, except EPS Reported %; Operational %1 Sales Adjusted earnings2 Adjusted EPS2 5.9%; 6.0%1 GAAP earnings (6.8)% Q3 2026 Q3 2025 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website 3 Includes the impact of a one-time special charge related to the proposed talc litigation resolution, as well as expenses related to the acquisition of Firefly Bio, Inc. and strategic collaboration with Sail Biomedicines 4 Includes expenses related to the acquisition of Firefly Bio, Inc. and strategic collaboration with Sail Biomedicines 3rd Quarter 2026 financial highlights GAAP EPS 16 Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 2026 Q3 2025 (95.9)% (95.8)% $0.23 $5.2 $0.093 $2.12 Includes one- time special charges Includes one- time special charges
Slide 17 — $16,757
1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded Other $2,560 Neuroscience $2,375 Oncology $7,602 Immunology $4,221 ■ Reported growth ■ Operational growth1 $16,757 7.7%, 7.9% WW sales $MM Key drivers of operational performance1 Oncology • DARZALEX increase primarily driven by strong share gains and market growth • CARVYKTI increase driven by share gains and continued site expansion • TECVAYLI growth driven by share gains following U.S. TECVAYLI + DARZALEX FASPRO approval • TALVEY growth driven by share gains from expansion in the community setting • RYBREVANT/LAZCLUZE growth driven by launch uptake and share gains • ERLEADA increase driven by continued share gains in mCSPC and market growth, partially offset by unfavorable patient mix • IMBRUVICA decrease driven by share loss due to continued competitive pressure and unfavorable patient mix • OTHER ONCOLOGY growth driven by INLEXZO U.S. launch uptake Immunology • TREMFYA growth due to share gains across all indications with significant IBD launch momentum and market growth • SIMPONI/SIMPONI ARIA and REMICADE decrease driven by share loss, biosimilar competition, and unfavorable patient mix, partially offset by market growth • STELARA decline driven by the impact of biosimilar competition and increasing adoption of novel classes • OTHER IMMUNOLOGY increase driven by IMAAVY and ICOTYDE launch uptake in the U.S. Neuroscience • SPRAVATO growth driven by continued share gains, supported by increased patient demand due to strong physician adoption • CAPLYTA growth driven by strong continued momentum in the aMDD launch and continued demand across bipolar disorder and schizophrenia • INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA increase primarily driven by favorable patient mix and inventory dynamics, partially offset by share loss Other • UPTRAVI flat due to unfavorable patient mix, partially offset by market growth • OPSUMIT/OPSYNVI decrease driven by lower demand following U.S. generic entrants • PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA decrease driven by declines in share and market, partially offset by favorable patient mix • XARELTO increase driven by favorable patient mix, partially offset by continued share erosion Adjusted operational sales2: WW 8.0%, U.S. 11.1%, Int’l 3.2% Innovative Medicine highlights – 3rd quarter 2026 Reported: WW 7.7%, U.S. 11.1%, Int’l 2.4% Operational1: WW 7.9%, U.S. 11.1%, Int’l 3.0% 1.3%, 1.4% 16.4%, 16.7% (9.9)%, (9.6)% Strong operational growth1 of 7.9% driven primarily by new product launches 17.3%, 17.6% 17 Stelara impacted results1 by ~(690) basis points
Slide 18 — $8,642
Surgery $2,528 Orthopaedics $2,345 Vision $1,461 Cardiovascular $2,307 ■ Reported growth ■ Operational growth1 $8,642 2.5%, 2.5% WW sales $MM Modest operational growth1 of 2.5% driven primarily by commercial execution and innovation Reported: WW 2.5%, U.S. 4.8%, Int’l 0.1% Operational1: WW 2.5%, U.S. 4.8%, Int’l 0.1% 4.3%, 4.1% 4.4%, 5.1% (0.6)%, (1.0)% 3.2%, 3.4% MedTech highlights – 3rd quarter 2026 1 Non-GAAP measure; excludes the impact of translational currency; see reconciliation schedules on the Investor Relations section of the company's website 2 Non-GAAP measure; excludes acquisitions and divestitures and translational currency; see reconciliation schedules on the Investor Relations section of the company's website Note: Values may be rounded 18 Key drivers of operational performance1 Cardiovascular • Electrophysiology: Increase driven by procedure growth, commercial execution, and new product performance (VARIPULSE, TRUPULSE, CRYSTAL, DUAL ENERGY STSF), partially offset by competitive pressures in PFA and OUS inventory dynamics • Abiomed: Decline driven by lower patient volumes, partially offset by sustained adoption of Impella 5.5 • Shockwave: Double-digit growth driven by continued strong adoption of Coronary and Peripheral portfolios and new product launches (AERO C2) Surgery Surgery decline driven by VBP in China, impact of the surgery transformation program, and disruptions in the Middle East • Advanced: • Biosurgery: ~ +3% growth driven by continued strength of the portfolio and commercial execution, partially offset by the impact of the surgery transformation program and VBP in China • Endocutters: ~ -4% due to VBP in China, impact of the surgery transformation program, and competitive pressures, partially offset by new products • Energy: ~ 0% driven by impact of the surgery transformation program, VBP in China, and competitive pressures, partially offset by new product launches • General: Decrease primarily driven by VBP in China, partially offset by technology penetration and upgrades within our differentiated Wound Closure portfolio (Barbed & PLUS Sutures) and market expansion Vision • Contact Lenses/Other: Increase driven by strong performance of the ACUVUE OASYS 1-Day family of products including recent launches and strategic price actions, partially offset by inventory dynamics • Surgical: Growth driven by strength of recent product innovations, robust demand for premium IOLs, and strong commercial execution, partially offset by disruptions in the Middle East Orthopaedics • Hips: Increase driven by new product launches (EMPHASYS) • Knees: Increase driven by strength of the ATTUNE portfolio, in part driven by pull- through related to the VELYS Robotic assisted solutions • Trauma: Growth driven by recently launched products (VOLT) and commercial execution, partially offset by OUS inventory dynamics • Spine, Sports & Other: ~ Flat due to new product innovations, partially offset by competitive pressures and inventory dynamics Adjusted operational sales2: WW 2.5%, U.S. 4.8%, Int’l 0.1%
Slide 19 — Condensed consolidated statement of earnings
2026 2025 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $25,399 100.0 $23,993 100.0 5.9 Cost of products sold 8,097 31.9 7,303 30.4 10.9 Gross Profit 17,302 68.1 16,690 69.6 3.7 Selling, marketing and administrative expenses 6,285 24.7 5,922 24.7 6.1 Research and development expense 4,652 18.3 3,672 15.3 26.7 In-process research and development impairments 339 1.4 - - Interest (income) expense, net 31 0.1 18 0.1 Other (income) expense, net 5,780 22.8 (478) (2.0) Restructuring 181 0.7 63 0.3 Earnings before provision for taxes on income 34 0.1 7,493 31.2 (99.5) (Benefit from)/Provision for taxes on income (176) (0.7) 2,341 9.7 (107.5) Net Earnings $210 0.8 $5,152 21.5 (95.9) Net earnings per share (Diluted) $0.09 $2.12 (95.8) Average shares outstanding (Diluted) 2,448.6 2,428.6 Effective tax rate (517.6)% 31.2% Adjusted earnings before provision for taxes and net earnings1 Earnings before provision for taxes on income $7,672 30.2 $8,436 35.2 (9.1) Net earnings $6,339 25.0 $6,801 28.3 (6.8) Net earnings per share (Diluted) $2.59 $2.80 (7.5) Effective tax rate 17.4% 19.4% 1 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website (Unaudited; Dollars and shares in millions except per share figures) 19 3rd Quarter 2026 Condensed consolidated statement of earnings
Slide 20 — Adjusted earnings before provision for taxes on income by segment
Innovative Medicine (2026 includes the impact of M&A transactions: Firefly Bio, Inc. & Sail Biomedicines) 2026 2025 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $16,757 100.0 $15,563 100.0 7.7 Cost of products sold 3,740 22.3 3,093 19.9 20.9 Gross Profit $13,017 77.7 $12,470 80.1 4.4 Selling, marketing and administrative expenses 3,035 18.1 2,869 18.4 5.8 Research and development expense 1 3,888 23.2 2,944 18.9 32.1 Other segment items 2,3 165 1.0 (238) (1.5) Adjusted segment income before tax 4 $5,929 35.4 $6,895 44.3 (14.0) (Unaudited; Dollars in millions) Adjusted earnings before provision for taxes on income by segment 20 MedTech 2026 2025 % Increase (Decrease) Amount % to Sales Amount % to Sales Sales to customers $8,642 100.0 $8,430 100.0 2.5 Cost of products sold 3,100 35.9 3,119 37.0 (0.6) Gross Profit $5,542 64.1 $5,311 63.0 4.3 Selling, marketing and administrative expenses 2,976 34.4 2,801 33.2 6.2 Research and development expense 759 8.8 728 8.6 4.3 Other segment items 2 (173) (2.0) 15 0.2 Adjusted segment income before tax 4 $1,980 22.9 $1,767 21.0 12.1 Enterprise (2026 includes the impact of M&A transactions: Firefly Bio, Inc. & Sail Biomedicines) 2026 2025 % Increase (Decrease) Amount % to Sales Amount % to Sales Adjusted income before tax 1,3,4 $7,672 30.2 $8,436 35.2 (9.1) 3rd Quarter 2026 1 Includes expenses related to the acquisition of Firefly Bio, Inc. 2 Includes other Income and Expense 3 Includes transaction costs related to the strategic collaboration with Sail Biomedicines 4 Non-GAAP measure; excludes intangible amortization expense and special items; see reconciliation schedules on the Investor Relations section of the company's website Note: For expenses not allocated to segments, see reconciliation schedules on the Investor Relations section of the company's website
Slide 21 — Joseph J. Wolk
Joseph J. Wolk Executive Vice President, Chief Financial Officer
Slide 22 — Capital allocation strategy
Capital allocation Organic growth business needs Free cash flow1 Priorities are clear and remain unchanged Competitive dividends Share repurchases Higher priority Lower priority Investment in M&A Dollars in billions Q3 2026 Cash and marketable securities $17 Debt ($45) Net debt ($28) Free cash flow1,2 ~$15 Q3 2026: $4.7B invested in R&D $11.8B year-to-date $3.2B in dividends paid to shareholders $9.6B year-to-date Note: Values may be rounded 1 Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment 2 Estimated as of October 13, 2026. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings Note: Values may be rounded Capital allocation strategy 22
Slide 23 — 2026 P&L guidance
Operational2 sales guidance of 6.9% and adjusted operational EPS2,4 at 2.0% (midpoints) October 2026 July 29, 2026 Comments Adjusted operational sales1,2 6.4% - 6.8% 6.2% - 6.8% Tightening range; Increasing midpoint to 6.6% Operational sales2 $100.5B - $100.9B 6.7% - 7.1% $100.3B - $100.9B 6.5% - 7.1% Tightening range; Increasing midpoint by $0.1B to 6.9% Estimated reported sales 3 $101.0B - $101.4B 7.2% - 7.6% $100.8B - $101.4B 7.0% - 7.6% Tightening range; Increasing midpoint by $0.1B to 7.4% Maintaining FX impact of $0.5B or 0.5% Adjusted pre-tax operating margin4,5 Decrease of approximately 60 bps Decrease of approximately 75 bps Improving Net other income4 $0.8 - $1.0 billion $1.0 - $1.2 billion Decreasing Net interest expense / (income) $150 - $200 million $250 - $350 million Decreasing and tightening range Effective tax rate4 17.0% - 17.5% 17.0% - 18.0% Decreasing and tightening range Adjusted EPS (operational)2,4 $10.95 - $11.05 1.5% - 2.4% $10.86 - $11.01 0.7% - 2.1% Increasing and tightening range; Increasing midpoint by $0.06 to 2.0% Adjusted EPS (reported)3,4 $11.05 - $11.15 2.4% - 3.3% $10.96 - $11.11 1.6% - 3.0% Increasing and tightening range; Increasing midpoint by $0.06 to 2.9% Maintaining FX impact of $0.10 or 0.9% 2026 P&L guidance 1 Non-GAAP measure; excludes acquisitions and divestitures 4 Non-GAAP measure; excludes intangible amortization expense and special items 2 Non-GAAP measure; excludes the impact of translational currency 5 Sales less: COGS, SM&A and R&D expenses 3 Calculated using Euro Average Rate: October 2026 = $1.15 and July 2026 = $1.15 Note: Values may be rounded 23
Slide 24 — 2026 milestones
Innovative Medicine 2026 milestones 1 driving long-term value creation MedTech 24 TECVAYLI + TALVEY in RRMM Pasritamig in prostate cancer JNJ-6143 in prostate cancer INLEXZO in HR NMIBC ICOTYDE in PsA CAPLYTA in bipolar mania TREMFYA in PsA SD nipocalimab in wAIHA and SLE Dual Energy THERMOCOOL STSF C2 Aero Catheters VARIPULSE Pro OTTAVA ETHICON 4000 TECNIS PureSee IOL MONARCH Urology VOLT suite of products 1 List above is not inclusive of all 2026 anticipated milestones across approvals, planned submissions, potential clinical data presentations, and launches RRMM: Relapsed/refractory multiple myeloma; HR NMIBC: High-risk non-muscle invasive bladder cancer; PsA: Psoriatic arthritis; PsA SD: Psoriatic arthritis structural damage; WAIHA: Warm autoimmune hemolytic anemia; SLE: Systemic lupus erythematosus; STSF: SMARTTOUCH Surround Flow; IOL: Intraocular lens
Slide 25 — Q&A
Q&A John Reed Executive Vice President, Innovative Medicine, R&D Joaquin Duato Chairman and Chief Executive Officer Joseph J. Wolk Executive Vice President, Chief Financial Officer Ryan Koors Vice President, Investor Relations Tom Cavanaugh Executive Vice President, Worldwide Chairman, Innovative Medicine Tim Schmid Executive Vice President, Worldwide Chairman, MedTech
Slide 26 — Slide footer goes here if required
Slide footer goes here if required 26
Slide 27 — Johnson & Johnson Innovative Medicine Pipeline
POTENTIAL APPROVALS US/EU PLANNED SUBMISSIONS US/EU POTENTIAL CLINICAL DATA PRESENTATIONS¹ Phase III Phase I/ II US TREMFYA (guselkumab) US IMAAVY (nipocalimab) US ERLEADA (apalutamide) ICOTYDE (icotrokinra) ERLEADA (apalutamide) JNJ-4804 Co-antibody Therapy Psoriatic Arthritis Structural Damage (APEX) Warm Autoimmune Hemolytic Anemia (ENERGY) EU Localized Prostate Cancer (ATLAS) Psoriasis (ICONIC-ASCEND) Localized Prostate Cancer (ATLAS) Ulcerative Colitis (DUET-UC) US ICOTYDE (icotrokinra) US CAPLYTA (lumateperone) US ERLEADA (apalutamide) ICOTYDE (icotrokinra) ERLEADA (apalutamide) JNJ-4804 Co-antibody Therapy EU Psoriasis (ICONIC) Bipolar Mania EU High Risk Prostate Cancer (PROTEUS) Psoriasis (ICONIC-ADVANCE 1&2 Update) High Risk Prostate Cancer (PROTEUS) Crohn's Disease (DUET-CD) US IMAAVY (nipocalimab) US bleximenib icotrokinra TALVEY (talquetamab) JNJ-4804 Co-antibody Therapy Warm Autoimmune Hemolytic Anemia (ENERGY) Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1) Psoriatic Arthritis (ICONIC- PsA) Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3) Psoriatic Arthritis (AFFINITY) AKEEGA (niraparib/abiraterone) US TALVEY (talquetamab) ICOTYDE (icotrokinra) TALVEY (talquetamab) nipocalimab EU M1 Metastatic Castration- Sensitive Prostate Cancer (AMPLITUDE) EU Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3) Psoriasis (ICONIC-TOTAL Update) Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6) Systemic Lupus Erythematosus (JASMINE) US DARZALEX (daratumumab) US TALVEY (talquetamab) CAPLYTA (lumateperone) TECVAYLI (teclistamab) bleximenib Frontline multiple myeloma transplant ineligible (CEPHEUS) EU Relapsed Refractory Multiple Myeloma CD38 exposed (MonumenTAL-6) Bipolar Mania (ITI-007-451) Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9) Relapsed Refractory Acute Myeloid Leukemia (cAMeLot-1) US TECVAYLI (teclistamab) US TECVAYLI (teclistamab) CAPLYTA (lumateperone) INLEXZO (gemcitabine intravesical delivery system) pasritamig + JNJ-9401 EU Multiple Myeloma 1-3PLs (MajesTEC-3) EU Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9) Bipolar Mania (ITI-007-452) High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5) Prostate Cancer (PCR1001) TECVAYLI (teclistamab) TECVAYLI (teclistamab) IMAAVY (nipocalimab) JNJ-6143 (HLD-0915) EU Relapsed Refractory Multiple Myeloma CD38 exposed (MajesTEC-9) EU Multiple Myeloma 1-3PLs (MajesTEC-3) Warm Autoimmune Hemolytic Anemia (ENERGY) Prostate Cancer (FIH Update) US RYBREVANT (amivantamab) US RYBREVANT (amivantamab) Head and Neck Cancer (ORIGAMI-4) Head and Neck Cancer (ORIGAMI-4) US INLEXZO (gemcitabine intravesical delivery system) EU High Risk Non Muscle Invasive Bladder Cancer BCG Experienced (SunRISe-5) Johnson & Johnson Innovative Medicine Pipeline Key Events in 2026* 1. In order to be on key events clinical presentation, data must be presented at a major medical meeting. *This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of October 13, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.